One of the most respected and influential groups in the continuing breast-cancer screening debate said on Tuesday that women should begin mammograms later and have them less frequently than it had long advocated.
The American Cancer Society,
 which has for years taken the most aggressive approach to screening, 
issued new guidelines on Tuesday, recommending that women with an 
average risk of breast cancer
 start having mammograms at 45 and continue once a year until 54, then 
every other year for as long as they are healthy and expected to live 
another 10 years.
The
 organization also said it no longer recommended clinical breast exams, 
in which doctors or nurses feel for lumps, for women of any age who have
 had no symptoms of abnormality in the breasts.
Previously, the society recommended mammograms and clinical breast exams every year, starting at 40.
The
 changes reflect increasing evidence that mammography is imperfect, that
 it is less useful in younger women, and that it has serious drawbacks, 
like false-positive results that lead to additional testing, including 
biopsies.
But
 the organization’s shift seems unlikely to settle the issue. Some other
 influential groups recommend earlier and more frequent screening than 
the cancer society now does, and some recommend less, leaving women and 
their doctors to sort through the conflicting messages and to figure out
 what makes the most sense for their circumstances.
In fact, although the new guidelines may seem to differ markedly from the old ones, the American Cancer Society
 carefully tempered its language to leave plenty of room for women’s 
preferences. Though it no longer recommends mammograms for women ages 40
 to 44, it said those women should still “have the opportunity” to have 
the test if they choose to, and that women 55 and older should be able 
to keep having mammograms once a year.
This year, 231,840 new cases of invasive breast cancer and 40,290 deaths are expected in the United States.
The new guidelines were published on Tuesday in the Journal of the American Medical Association, along with an editorial and an article on the benefits and risks of screening, which provided evidence for the guidelines. A separate article and editorial on the subject were also published in another journal, JAMA Oncology.
The
 guidelines apply only to women at average risk for breast cancer — 
those with no personal history of the disease or known risk factors 
based on genetic mutations, family history or other medical problems.
The
 changed policy resulted from an exhaustive review of research data, 
which the cancer society conducts regularly to update its screening 
guidelines, said Dr. Richard C. Wender, the organization’s chief cancer 
control officer. The last review was in 2003, and this one took about 
two years.
 Dr. Wender said he hoped the new guidelines would end some of the debate
 and confusion about mammography. But some doubted that the guidelines 
would bring clarity.
“I
 think it has the potential to create a lot of confusion amongst women 
and primary care providers,” said Dr. Therese B. Bevers, the medical 
director of the Cancer Prevention Center at the University of Texas M. 
D. Anderson Cancer Center in Houston.
Dr.
 Nancy L. Keating, a professor of health care policy and medicine at 
Harvard and a co-author of the JAMA editorial about the guidelines, said
 she thought the new advice had been thoughtfully developed and was 
headed in the right direction. Dr. Keating, who practices at Brigham and
 Women’s Hospital in Boston, said doctors and patients had clung to the 
practice of early and yearly mammograms out of fear that they would 
otherwise miss detecting a cancer.
The National Comprehensive Cancer Network, an alliance of prominent cancer centers, recommends mammograms every year starting at age 40. The American College of Obstetricians and Gynecologists
 recommends them every year or two from ages 40 to 49, and every year 
after that. It also recommends yearly clinical breast exams starting at 
age 19.
The
 obstetricians’ group said it was convening a conference in January, 
with the participation of the American Cancer Society, the comprehensive
 cancer network and other organizations, to try to develop a consistent 
set of guidelines.
Among those invited are the United States Preventive Services Task Force,
 which recommends less testing: mammograms every other year for women 
ages 50 to 74. In 2009, it advised against routine mammograms for women 
ages 40 to 49, a decision that ignited a firestorm of protests from 
doctors, patients and advocacy groups.
The
 task force, an independent panel of experts appointed by the Department
 of Health and Human Services, softened its approach in draft guidelines
 that were posted on its website in April and have yet to be finalized. 
Instead of advising against routine screening for women in their 40s, 
the group now says, “The decision to start screening mammography in 
women before age 50 years should be an individual one.”
But
 the task force gave the evidence for screening women under 50 a rating 
of “C,” reflecting its belief that the benefit is small. Services with a
 C rating do not have to be covered by the Affordable Care Act, 
according to the Department of Health and Human Services — a serious 
worry for advocates.
 In response to the new cancer society guidelines, the task force issued a
 statement saying it would “examine the evidence” the cancer society had
 developed and reviewed before finalizing its recommendations. The 
statement also noted that the task force recognized “that there are 
health benefits to beginning mammography screening for women in their 
40s.”
In
 making recommendations about screening, experts try to balance the 
benefits of a test against its potential harms for women in various age 
groups. A general explanation of the reasoning behind the new guidelines
 is that breast cancer is not common enough in women under 45 to make 
mammograms worthwhile for that age group, but that the risk of the 
disease increases enough to justify screening once a year after that. 
Specifically, the risk of developing breast cancer during the next five 
years is 0.6 percent in women ages 40 to 44; 0.9 percent from 45 to 49; 
and 1.1 percent from 50 to 54.
The risk keeps increasing slowly with age, but by 55, when most women have passed through menopause,
 tumors are less likely to be fast-growing or aggressive, and breast 
tissue changes in ways that make mammograms easier to read — so 
screening every other year is considered enough.
As
 for the decision to stop recommending clinical breast exams, the 
society said that there was no evidence that the exams save lives, but 
that there was evidence that they could cause false positives — meaning 
they could mistakenly suggest problems where none existed and lead to 
more tests. The exams can take five or six minutes that could be put to 
better use during office visits, said Dr. Kevin C. Oeffinger, the 
chairman of the cancer-society subgroup that developed the guidelines 
and director of cancer survivorship at Memorial Sloan Kettering Cancer 
Center in New York.
According
 to the evidence review accompanying the guidelines, the benefit of 
regular mammography is that it can reduce the risk of dying from breast 
cancer by about 20 percent. Because breast cancer is less common in 
younger women, their baseline risk of dying is lower, and screening them
 saves fewer lives.
While
 younger women have less to gain from mammograms, the cancer society 
found, they incur all the potential harms. One harm is false positives, 
which can lead to more tests, including biopsies. A 2011 study cited in 
the article explaining the new guidelines found that 61 percent of women
 who had yearly mammograms starting at age 40 had at least one false 
positive by the time they were 50. Being tested every other year instead
 of every year can cut the false positive rate significantly, the JAMA 
Oncology article explaining the guidelines said, to about 42 percent 
from 61 percent.
Some
 women consider false positives a small price to pay for the chance of 
identifying a cancer early. Others find being called back for more tests
 too nerve-racking.
Another
 potential risk of mammography is overdiagnosis, meaning that some of 
the tiny cancers it finds might never progress or threaten the patient’s
 life. But because there is now no way to be sure which will turn 
dangerous, they are treated anyway.
There
 are no widely accepted figures on how often overdiagnosis occurs. 
Researchers think that it is mostly likely in women found to have ductal
 carcinoma in situ, or D.C.I.S., tiny growths in the milk ducts that may
 or may not evolve into invasive cancer. About 60,000 cases of D.C.I.S. 
are diagnosed in the United States each year.
“We
 would all love to avoid diagnosing and treating a breast cancer that 
doesn’t need treatment,” Dr. Oeffinger said. “But we don’t have the 
tools.”
But,
 he added: “This area is rapidly changing. In five to seven years, we’ll
 have more knowledge in this area that will let us be more personalized 
in our approach.”
Dr.
 Keating said, “Radiologists are working hard to find new and better 
screening tests, which we desperately need, but I think it will take 
time.”
 
 
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου